Harvard Bioscience (HBIO) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 2, 2026, at 10:00 AM ET, with virtual participation available.

• Shareholders are invited to vote on key proposals, including director elections, auditor ratification, executive compensation, and amendments to equity plans.

Voting matters and shareholder proposals

• Election of two Class II Directors: John Duke and Katherine A. Eade, both recommended by the Board.

• Ratification of Grant Thornton LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote on executive compensation for named executive officers.

• Approval of amendments to increase authorized shares in the Employee Stock Purchase Plan by 120,000 shares.

• Approval of amendments to increase authorized shares in the 2021 Incentive Plan by 400,000 shares.

Board of directors and corporate governance

• Board recommends all proposals, including director nominees and plan amendments, for shareholder approval.